Prognostic Understanding at Diagnosis and Associated Factors in Patients with Advanced Lung Cancer and Their Caregivers
Takashi Sato(Kitasato University), Tomoko Betsuyaku(Tokyo Medical University), Kenzo Soejima(Keio University), Takashi Inoue(Ome Municipal General Hospital), Kota Hikima(Sapporo Kosei General Hospital), Shigenari Nukaga(Tokyo Medical Center), Fumitake Saito(Eiju General Hospital), Keigo Kobayashi(Osaka Gakuin University), Keiko Ohgino(Keio University), Katsunori Masaki(Keio University), Fumio Sakamaki(Keio University), Kota Ishioka(Keio University), Ichiro Nakachi(Saiseikai Utsunomiya hospital), Daisuke Fujisawa(Keio University), Morio Nakamura(Saiseikai Central Hospital), Daisuke Arai(Keio University), Hiroyuki Yasuda(Beth Israel Deaconess Medical Center), Yohei Funatsu(Keio University), Ichiro Kawada(Keio University), Katsuhiko Naoki(Broad Institute), Koichi Sayama(Beth Israel Deaconess Medical Center), Naoki Miyao, Takeshi Terashima(Keio University), Mari Takeuchi(Keio University), Yoshitaka Oyamada(Keio University)
Cited by 47
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Plasma Brain Natriuretic Peptide as a Prognostic Indicator in Patients With Primary Pulmonary Hypertension
|Circulation|2000|880
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|642
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
|Science Translational Medicine|2013|565